Cargando…

Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study

AIMS/INTRODUCTION: The EMPA‐REG OUTCOME® trial demonstrated benefits of empagliflozin, a sodium‐glucose cotransporter‐2 inhibitor (SGLT2i), on cardiovascular, renal outcomes and all‐cause mortality in patients with type 2 diabetes and established cardiovascular disease. The EMPRISE study program eva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Dae Jung, Sheu, Wayne H‐H, Chung, Wook‐Jin, Yabe, Daisuke, Ha, Kyoung Hwa, Nangaku, Masaomi, Tan, Elise Chia‐Hui, Node, Koichi, Yasui, Atsutaka, Lei, Weiyu, Lee, Sunwoo, Saarelainen, Laura, Deruaz‐Luyet, Anouk, Kyaw, Moe H, Seino, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951576/ https://www.ncbi.nlm.nih.gov/pubmed/36716212 http://dx.doi.org/10.1111/jdi.13959

Ejemplares similares

Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study
por: Seino, Yutaka, et al.
Publicado: (2020)

Healthcare resource utilization in patients treated with empagliflozin in East Asia
por: Sheu, Wayne H‐H, et al.
Publicado: (2022)

The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care
por: Patorno, Elisabetta, et al.
Publicado: (2019)

Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
por: Vistisen, Dorte, et al.
Publicado: (2023)

L'emprise : roman /
por: Brulotte, Gaétan
Publicado: (1979)

L'Emprise de l'organisation /
Publicado: (1998)

Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes
por: Yabe, Daisuke, et al.
Publicado: (2021)

L'emprise des enfants entre nous /
por: Schérer, René
Publicado: (1979)

Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I–III clinical trials
por: Yabe, Daisuke, et al.
Publicado: (2018)

Le harcèlement organisationnel: des relations sous emprise
por: Guhel, Cécile
Publicado: (2014)

Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs
por: Schernthaner, Guntram, et al.
Publicado: (2019)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
por: Htoo, Phyo T., et al.
Publicado: (2022)

Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: Real world evidence from the Nordic EMPRISE study
por: Nyström, Thomas, et al.
Publicado: (2022)

The clinical burden of newly diagnosed Heart failure among patients with Reduced, mildly Reduced, and preserved ejection fraction
por: Nichols, Gregory A., et al.
Publicado: (2023)

Epidemiology of Asymptomatic Pre-heart Failure: a Systematic Review
por: Bergamasco, Aurore, et al.
Publicado: (2022)

Potential paraneoplastic syndromes and selected autoimmune conditions in patients with non-small cell lung cancer and small cell lung cancer: A population-based cohort study
por: Miret, Montserrat, et al.
Publicado: (2017)

Prevalence of multimorbidity in general practice: a cross-sectional study within the Swiss Sentinel Surveillance System (Sentinella)
por: Excoffier, Sophie, et al.
Publicado: (2018)

Incidence of lower extremity amputations among patients with type 1 and type 2 diabetes in the United States from 2010 to 2014
por: Déruaz‐Luyet, Anouk, et al.
Publicado: (2020)

Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
por: Yasui, Atsutaka, et al.
Publicado: (2018)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME(®) trial
por: Kadowaki, Takashi, et al.
Publicado: (2019)

The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease
por: Kaku, Kohei, et al.
Publicado: (2022)

Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study
por: Terauchi, Yasuo, et al.
Publicado: (2019)

Comparing the self-perceived quality of life of multimorbid patients and the general population using the EQ-5D-3L
por: N’Goran, Alexandra A., et al.
Publicado: (2017)

Correction to: Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes
por: Nichols, Gregory A., et al.
Publicado: (2020)

Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes
por: Nichols, Gregory A., et al.
Publicado: (2020)

Ambivalence, emprise, soutien. De la difficulté d’entourer le patient âgé à « suffisamment bonne » distance()
por: Verdon, Benoît, et al.
Publicado: (2021)

Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial
por: Shimada, Akira, et al.
Publicado: (2018)

Dietary recommendations for type 2 diabetes patients: Lessons from recent clinical and basic research in Asia
por: Seino, Yusuke, et al.
Publicado: (2019)

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials
por: Tuttle, Katherine R., et al.
Publicado: (2022)

Empagliflozin in Patients with Chronic Kidney Disease
por: Herrington, William G., et al.
Publicado: (2023)

Family practitioners' top medical priorities when managing patients with multimorbidity: a cross-sectional study
por: Herzig, Lilli, et al.
Publicado: (2019)

Factors associated with health literacy in multimorbid patients in primary care: a cross-sectional study in Switzerland
por: N’Goran, Alexandra A, et al.
Publicado: (2018)

Determinants associated with deprivation in multimorbid patients in primary care—A cross-sectional study in Switzerland
por: Leiser, Silja, et al.
Publicado: (2017)

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)
por: Green, Jennifer B, et al.
Publicado: (2022)

Impact of vaccination and non-pharmacological interventions on COVID-19: a review of simulation modeling studies in Asia
por: Thakkar, Karan, et al.
Publicado: (2023)

A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues
por: Wada, Takehiko, et al.
Publicado: (2015)

Multimorbidity in primary care: protocol of a national cross-sectional study in Switzerland
por: Déruaz-Luyet, Anouk, et al.
Publicado: (2015)

Empagliflozin in the treatment of type 2 diabetes: evidence to date
por: Shubrook, Jay H, et al.
Publicado: (2015)

Outbreaks of meningococcal meningitis in non-African countries over the last 50 years: a systematic review
por: van Kessel, Femke, et al.
Publicado: (2019)

Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rjdvpkhth8r2gh0gsifrm1b44d